New insights into the biological therapy of Crohn’s disease

Author： Hassan Cesare   Zullo Angelo   Campo Salvatore MA   Morini Sergio  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.15, Iss.4, 2005-04, pp. : 409-419

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy of Crohn’s disease in childhood

By Beattie R Mark   Bremner A Ronald F  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 809-825

Informa Healthcare

Access to resources Recommend Favorite

Economic Implications of Biological Therapies for Crohn’s Disease: Review of Infliximab

By Bodger Keith  

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 875-888

Adis International

Access to resources Recommend Favorite

Novel therapy for Crohn’s disease targeting IL-6 signalling

By Ito Hiroaki  

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 4, 2004-08 ,pp. : 287-294

Informa Healthcare

Access to resources Recommend Favorite

Infliximab: a biological breakthrough in Crohn's disease therapy

By  

Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Pharmacogenomics of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease

By Shetty A.   Forbes A.  

American Journal of PharmacoGenomics, Vol. 2, Iss. 4, 2002-01 ,pp. : 215-221

Adis International

Access to resources Recommend Favorite